Company news

iSpecimen Inc. news in 2024

iSpecimen Inc.'s news releases, calls and decks from 2024, newest first.

View company

iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens

December 19, 2024

iSpecimen Appoints Robert Lim as CEO and Director

December 11, 2024

iSpecimen Reports Third Quarter 2024 Results

November 6, 2024

iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually

November 6, 2024

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

October 30, 2024

iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

October 29, 2024

iSpecimen Announces 1-for-20 Reverse Stock Split

September 10, 2024

iSpecimen Reports Second Quarter 2024 Results

August 5, 2024

iSpecimen to Report Second Quarter 2024 Results on August 6, 2024

July 24, 2024

iSpecimen Reports First Quarter 2024 Results

May 6, 2024

iSpecimen to Report First Quarter 2024 Financial Results on May 7, 2024

April 24, 2024

iSpecimen Reports Full Year 2023 Results

March 13, 2024

iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call

March 11, 2024

iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research

January 22, 2024

Calls in 2024

Decks in 2024